Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.16 EUR | +0.64% | -1.22% | -10.37% |
Mar. 18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
Mar. 18 | Fresenius Settles With Johnson & Johnson to Market Stelara Alternative | DJ |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Its low valuation, with P/E ratio at 10.01 and 7.85 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- One of the major weak points of the company is its financial situation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.37% | 15.33B | A- | ||
-11.31% | 18.1B | B+ | ||
+4.50% | 12.84B | B | ||
+1.00% | 11.38B | B+ | ||
+7.58% | 10.38B | B+ | ||
+2.00% | 8.2B | A- | ||
+13.89% | 7.49B | B | ||
+8.89% | 6.9B | B- | ||
+6.98% | 6.45B | D | ||
+6.17% | 4.7B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Fresenius SE & Co. KGaA - Xetra
- Ratings Fresenius SE & Co. KGaA